Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy

被引:66
|
作者
Chulpanova, Daria S. [1 ]
Kitaeva, Kristina V. [1 ]
Green, Andrew R. [2 ]
Rizvanov, Albert A. [1 ,2 ]
Solovyeva, Valeriya V. [1 ]
机构
[1] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia
[2] Univ Nottingham, Nottingham Breast Canc Res Ctr, Div Canc & Stem Cells, Sch Med,Biodiscovery Inst, Nottingham, England
基金
俄罗斯科学基金会;
关键词
cancer immunotherapy; cytokines; anticancer immune responses; immune cell markers; populations; tumor microenvironment; NATURAL-KILLER-CELLS; CD8(+) T-CELLS; COLONY-STIMULATING FACTOR; PLASMACYTOID DENDRITIC CELLS; GROWTH-FACTOR-BETA; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE CHECKPOINT BLOCKADE; PHASE-1; CLINICAL-TRIAL; CD56(BRIGHT) NK CELLS; STAGE IV MELANOMA;
D O I
10.3389/fcell.2020.00402
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines, as proteins of the immune system, are able to modulate the host immune response toward cancer cell, as well as directly induce tumor cell death. Since a low dose monotherapy with some cytokines has no significant therapeutic results and a high dose treatment leads to a number of side effects caused by the pleiotropic effect of cytokines, the problem of understanding the influence of cytokines on the immune cells involved in the pro- and anti-tumor immune response remains a pressing one. Immune system cells carry CD makers on their surface which can be used to identify various populations of cells of the immune system that play different roles in pro- and anti-tumor immune responses. This review discusses the functions and specific CD markers of various immune cell populations which are reported to participate in the regulation of the immune response against the tumor. The results of research studies and clinical trials investigating the effect of cytokine therapy on the regulation of immune cell populations and their surface markers are also discussed. Current trends in the development of cancer immunotherapy, as well as the role of cytokines in combination with other therapeutic agents, are also discussed.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] Molecular and Macroscopic Therapeutic Systems for Cytokine-Based Cancer Immunotherapy
    Jin, Seung Mo
    Lee, Sang Nam
    Yoo, Yeon Jeong
    Lim, Yong Taik
    ADVANCED THERAPEUTICS, 2021, 4 (08)
  • [2] Cytokine-based immunotherapy for advanced kidney cancer: Past results and future perspectives in the era of molecularly targeted agents
    Porta, Camillo
    Paglino, Chiara
    Imarisio, Ilaria
    Bonomi, Lucia
    THESCIENTIFICWORLDJOURNAL, 2007, 7 : 837 - 849
  • [3] Th1 cytokine-based immunotherapy for cancer
    Hong-Mei Xu
    Hepatobiliary & Pancreatic Diseases International, 2014, 13 (05) : 482 - 494
  • [4] Th1 cytokine-based immunotherapy for cancer
    Xu, Hong-Mei
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2014, 13 (05) : 482 - 494
  • [5] Study on anti-cancer long-term effect of cytokine-based carrier drug
    Yan-qing, Guang
    Li-li, Qiu
    Rui-xue, Liao
    Xiao-dan, Qu
    Yu, Qiu
    Tian-hong, Zhou
    TISSUE ENGINEERING, 2006, 12 (04): : 1072 - 1072
  • [6] Cytokine-based immunotherapy of allergic disease
    Lewkowich, IP
    HayGlass, KT
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2001, 49 (04) : 293 - 302
  • [7] Revitalizing Cytokine-Based Cancer Immunotherapy through Advanced Delivery Systems
    Chen, Pengwen
    Paraiso, West Kristian Dizon
    Cabral, Horacio
    MACROMOLECULAR BIOSCIENCE, 2023, 23 (12)
  • [8] Cytokine-based immunotherapy of solid tumors (review)
    Fridman, WH
    Pages, F
    Lee, RS
    Mathiot, C
    Dorval, T
    Thiounn, N
    Pouillart, P
    Debre, B
    Tartour, E
    ONCOLOGY REPORTS, 1997, 4 : 235 - 240
  • [9] Anti-cancer immunotherapy: breakthroughs and future strategies
    Mads Hald Andersen
    Seminars in Immunopathology, 2019, 41 : 1 - 3
  • [10] Anti-cancer immunotherapy: breakthroughs and future strategies
    Andersen, Mads Hald
    SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (01) : 1 - 3